Plus Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, on March 27, 2025. The company highlighted promising safety and efficacy data for its lead drug REYOBIQ in its two most advanced CNS cancer programs.
The company noted that recently raised capital, coupled with existing grant support, enables the progression of both therapeutic programs to key clinical and regulatory milestones. This funding also supports the commercial launch of its CNSide diagnostic platform.
Management anticipates that 2025 has the potential to be transformational as the company expects to transition to an operational revenue-generating company with the launch of CNSide. The company did not provide specific revenue or net income figures in this press release.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.